Candel Therapeutics CADL Institutional Ownership

Candel Therapeutics, Inc. (NASDAQ:CADL) has 139 institutional investors that have filed 13F reports for the period ending June 2026.

• These investors held 68.5% of outstanding shares in June 2026, down from 82.3% in March 2026.
• They increased total shares held in Candel Therapeutics by 25.03% from the prior quarter, while the number of investors in CADL increased 80.52% year over year.
• During the quarter, 105 of these 139 funds increased positions in CADL, 23 reduced exposure, and 11 held steady.
• Altogether, these fund groups held 50.81Mn shares in CADL by June 2026, up by 10.17Mn shares quarter on quarter, and up 27.69Mn shares year over year.
• FMR LLC holds the largest position in CADL at 10.99Mn shares as of June 30, 2026, or 14.83% of shares outstanding.
• The biggest buyers of Candel Therapeutics for the quarter ending June 2026 included State Street Corp (2.73Mn), BlackRock, Inc. (1.86Mn), Portolan Capital Management, LLC (596.07K), GEODE CAPITAL MANAGEMENT, LLC (535.59K), Saturn V Capital Management LP (407.1K).
• The biggest sellers of Candel Therapeutics for the quarter ending June 2026 included Halter Ferguson Financial Inc. (131.59K), Kynam Capital Management, LP (103.26K), Ghisallo Capital Management LLC (100.0K), TWO SIGMA INVESTMENTS, LP (60.77K), Hudson Bay Capital Management LP (34.21K).
• Business Quant data shows the 10 biggest positions in Candel Therapeutics as of June 2026 are held by FMR LLC (10.99Mn), RTW INVESTMENTS, LP (6.42Mn), BlackRock, Inc. (4.97Mn), State Street Corp (3.55Mn), ACORN CAPITAL ADVISORS, LLC (3.5Mn), Portolan Capital Management, LLC (3.49Mn), Saturn V Capital Management LP (3.3Mn), VANGUARD CAPITAL MANAGEMENT LLC (2.69Mn), GEODE CAPITAL MANAGEMENT, LLC (1.57Mn), MILLENNIUM MANAGEMENT LLC (1.09Mn).